EN ZH NEWS NEWARK, CA • FEBRUARY 26, 2024 AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers – This first in human clinical study demonstrated that AL01211 was generally safe and well-tolerated at single doses up to 60 mg and at multiple doses up to 30 mg– AL01211 …
Author Archives: lili1997a
News 10312023
EN ZH NEWS NEWARK, CA • OCTOBER 31, 2023 AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease – Plan to enroll patients across six sites throughout China – – Topline results are expected in 2H 2024 – (BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation …
News 08102023
EN ZH NEWS NEWARK, CA • AUGUST 10, 2023 AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease (BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of …
News 06212023
EN ZH NEWS NEWARK, CA • JUNE 21, 2023 AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease (BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the …
News 05172023
EN ZH NEWS NEWARK, CA • MAY 17, 2023 AceLink Therapeutics to Present at World Orphan Drug Congress USA (BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders …
AL1311
EN ZH PIPELINE AL1311 is a highly potent NRF2 activator that is being developed for Autosomal Dominant Polycystic Kidney disease (ADPKD). AL1311 is different from other electrophilic and reactive NRF2 activators because it works by disrupting the protein-protein interaction between NRF2 and its regulatory protein Keap1. Non-reactive NRF2 activators have the potential to have better specificity …
AL0804
EN ZH PIPELINE AL0804 is a highly brain penetrant GCS inhibitor being developed for the treatment of neuronopathic glycolipid storage diseases including Gaucher disease (Type II and III), GM2 gangliosidosis (Tay-Sachs and Sandhoff disease), GM1 gangliosidosis, and certain genetic forms of Parkinson’s disease. AL0804 has superior potency and brain penetration compared to other brain penetrant GCS …
AL1211
EN ZH PIPELINE AL1211 is a glucosylceramide synthase (GCS) inhibitor with unique and superior properties to other GCS inhibitors currently approved or in development. AL1211 is more potent and has a better off-target activity profile than other GCS inhibitors. AL1211 also has excellent penetration into the tissues that are affected in Fabry disease like heart and …
GBA PARKINSON’S DISEASE
EN ZH SCIENCE GBA PARKINSON’S DISEASE GBA Parkinson’s disease is arguably the most common genetic form of Parkinson’s disease. Numerous genetic studies have shown that a single mutation in the GBA1 gene (the gene that causes Gaucher disease) can increase your risk of developing Parkinsons’ disease by up to 30-fold. In vitro and in vivo preclinical studies suggest that …
DIABETIC NEPHROPATHY (DN)
EN ZH SCIENCE DIABETIC NEPHROPATHY (DN) Diabetic nephropathy (DN) is a common form of kidney damage that occurs with the progression of metabolic diseases like type I and type II diabetes. If diabetes is not properly treated then damage can occur to the glomeruli, the filtration units of the kidney. This damage can lead to …